Trial Profile
A Phase 3 Randomized, Open Label Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor and Two Nucleoside Reverse Transcriptase Inhibitors to Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF) Fixed-dose Regimen in Virologically Suppressed, HIV-1 Infected Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors; Ritonavir
- Indications HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms SPIRIT
- Sponsors Gilead Sciences
- 09 May 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
- 28 Jan 2014 Status changed from active, no longer recruiting to completed according to results published in AIDS.
- 28 Jan 2014 Results published in the AIDS.